Read More

Kinnate Biopharma Inc. Adds Two New Drug Candidates To Its Growing Targeted Oncology Pipeline And Provides Cash Runway Guidance; ~$231M Of Cash, Cash Equivalents And Investments As Of March 31, 2023

KIN-7136, a next generation brain-penetrant MEK inhibitor for MAPK-driven advanced adult solid tumors, is expected to enter the clinic in the second half of 2023   KIN-8741, a highly selective c-MET inhibitor

KNTE

Read More

80 Years Post-Discovery, LSD Shows Significant Potential For Major Depression In Advanced Clinical Trial

Psychedelics biopharma company Mind Medicine Inc.’s (NASDAQ: MNMD) shared positive topline data from an advanced clinical trial evaluating its lysergide (aka LSD) for the treatment of Major Depressive Disorder (MDD) on Friday — just a couple of days before the 80th anniversary of the discov

MNMD